naratriptan
In two Phase III trials of naratriptan compared with placebo, relief at four       hours was obtained in 60% and 68% of patients using the 2.5-mg dose, with       recurrence of headache in 24 hours in 27% and 28% of patients.
In two Phase III trials of  @SUBJECT$   @PREDICAT$  with  @OBJECT$ , relief at four       hours was obtained in 60% and 68% of patients using the 2.5-mg dose, with       recurrence of headache in 24 hours in 27% and 28% of patients.